从资金流向来看，天益医疗当日主力资金净流出66.56万元，近五个交易日累计净流出1248.30万元。当 前公司总市值为27.93亿元，流通市值为8.69亿元。 风险提示：市场有风险，投资需谨慎。 来源：金融界 天益医疗最新股价为47.38元，较前一交易日上涨2.20%。该股开盘价为46.24元，最高触及48.17元，最 低下探45.64元，成交量为7191手，成交金额达0.34亿元。 天益医疗主营业务为医疗器械的研发、生产和销售。公司产品涵盖多个医疗领域，包括体外循环及血液 净化设备等。作为浙江地区的医疗企业，公司具有完整的产业链布局。 ...

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total compensation for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Group 1: CFO Compensation Overview - The average annual salary for CFOs in the A-share medical device sector is 908,600 yuan [2] - The distribution of CFO salaries shows that 24% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 29% earn between 1 million and 2 million yuan, and 5% earn above 2 million yuan [2] - The top three highest-paid CFOs are Dai Zhenhua from Huatai Medical at 2.70 million yuan, Rui Chenwei from Nanwei Medical at 2.65 million yuan, and Wu Jinhong from Guoke Hengtai at 1.77 million yuan [2] Group 2: CFO Demographics - The age distribution of CFOs shows that those aged 40-50 make up 57%, while 32% are over 50, and 11% are 40 or younger [1] - The youngest CFO is 31 years old, while the oldest is 60 years old [1] - In terms of educational background, 16% of CFOs have an associate degree, 66% hold a bachelor's degree, 16% have a master's degree, and only 2% possess a doctoral degree [1] Group 3: Salary Changes - Among CFOs with over two years of tenure, the largest salary decrease was observed for Kong Xiangqian from Aidi Te, with a decline of 16.86% year-on-year [2] - Conversely, the largest salary increase was for Song Yizhao from Shandong Glass, with a rise of 144.86% year-on-year [2]

Core Viewpoint - The medical device industry experienced a slight increase of 0.47% on July 28, with a net outflow of funds amounting to 295 million [1] Group 1: Market Performance - A total of 52 stocks in the sector rose, while 68 stocks declined [1] - The top-performing stocks included: - Aidi Te (16.88%) - Kehua Bio (10.01%) - Rejing Bio (6.88%) - Zhengchuan Co. (6.68%) - David Medical (6.55%) [1][1][1] Group 2: Fund Flow - The net capital flow for the top gainers was as follows: - Aidi Te: 106 million - Kehua Bio: 12 million - Rejing Bio: 21 million - Zhengchuan Co.: -14 million (outflow) [1][1][1] - Other notable stocks with positive fund flow included: - David Medical: -6 million (outflow) - Sainuo Medical: 6 million [1][1] Group 3: Declining Stocks - The stocks with the largest declines included: - Aohua Endoscopy (-4.09%) - Tianyi Medical (-2.73%) - Mountain Outside Mountain (-2.53%) - Ruimaite (-2.42%) - Jianfan Bio (-2.32%) [1][1][1] - Additional stocks that saw declines were: - Lude Medical (-2.22%) - Nanwei Medical (-2.14%) - San Nuo Bio (-2.13%) [1][1]

Group 1 - Tianyi Medical (301097) closed at 42.92 yuan on July 18, 2025, with an increase of 1.11% and a turnover rate of 6.02% [1] - The trading volume was 11,000 shares, with a total transaction amount of 47.0881 million yuan [1] - On the same day, the net inflow of main funds was 3.7363 million yuan, while the net outflow of speculative funds and retail investors was 2.8381 million yuan and 0.8982 million yuan, respectively [2][4] Group 2 - Tianyi Medical announced a change in the use of raised funds, terminating the "Comprehensive R&D Center Construction Project" of its subsidiary, Ningbo Tairis Technology Co., Ltd., and reallocating the remaining and over-raised funds to the "Thailand Production Base Construction Project" [2] - This change was approved by the shareholders' meeting on January 13, 2025, and the company has opened a special account for the raised funds at China Industrial Bank (Thailand) [2] - A five-party supervision agreement was signed to regulate the management of the raised funds, ensuring they are used solely for the "Thailand Production Base Construction Project" [3][4]

Core Viewpoint - Ningbo Tianyi Medical Instrument Co., Ltd. has announced the establishment of a special account for raised funds and signed a five-party supervision agreement for the management of these funds, shifting the focus from a previously planned project to a new project in Thailand [1][2]. Fundraising Basic Information - The company raised a total of 14736800 shares at an issuance price of RMB 52.37 per share, resulting in total fundraising of approximately RMB 772.5 million. After deducting related expenses of RMB 18.04 million, the net amount raised is RMB 694.56 million [1][2]. Changes in Fund Usage - The company has decided to terminate the original fundraising project for the "Comprehensive R&D Center Construction Project" and redirect all remaining funds to the new "Thailand Production Base Construction Project" [1][2]. Establishment of Special Fund Account - A special account for the raised funds has been established at the Industrial and Commercial Bank of China (Thailand) with the account number 5100303754, specifically for the Thailand production base project [2][3]. Five-Party Supervision Agreement - The five-party supervision agreement includes the company, its Singapore subsidiary, its Thai subsidiary, the Industrial and Commercial Bank of China (Thailand), and the sponsor, Guotai Junan Securities. This agreement aims to regulate the management of the raised funds and protect the rights of small investors [5][6]. Fund Transfer Process - The process for transferring the remaining funds involves several steps, including returning funds from the subsidiary to the company and then transferring them to newly established accounts for both RMB and USD at the Shanghai Pudong Development Bank [2][4]. Completion of Fund Management Steps - The company has completed the necessary steps for fund management, including the reduction of capital for its subsidiary and the establishment of both RMB and USD special accounts at the Shanghai Pudong Development Bank [3][4].

证券代码：301097 证券简称：天益医疗 公告编号：2025-039 宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 并签署募集资金五方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"或"公司"）于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》，同意变更募集资金用途，同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目"，并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目"；同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日，公司已完成在中国工商银行（泰国）股份有限公司募集 资金专项账户的开立及募集资金五方监管协议的签署，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开 ...

Group 1 - The A-share medical device sector experienced a short-term surge, with Baolait rising over 17% [1] - Other stocks such as Jinan Development, Yangpu Medical, Tianyi Medical, Diri Medical, Guanhao Biological, and Chunli Medical also saw increases [1] - The rise in stock prices is attributed to the Chinese government's procurement measures affecting medical devices imported from the European Union [1]

Core Viewpoint - Ningbo Tianyi Medical Instrument Co., Ltd. has announced a change in the use of raised funds, terminating the original project for the "Comprehensive R&D Center Construction Project" and reallocating the remaining funds to the new "Thailand Production Base Construction Project" [1][2]. Fundraising Basic Information - The company raised a total of RMB 771.77 million by issuing 14.7368 million shares at RMB 52.37 per share, with net proceeds amounting to RMB 694.56 million after deducting various fees [1]. - The funds were verified by Lixin Accounting Firm, which issued a verification report [1]. Fundraising Special Account and Supervision Agreement - The company has established a special fundraising account at Shanghai Pudong Development Bank, Ningbo High-tech Zone Branch, for the new project [2][3]. - The company has signed a tripartite supervision agreement with the bank and its sponsor, Guotai Junan Securities, to oversee the use of the raised funds [3][4]. Tripartite Supervision Agreement Key Points - The special accounts for RMB and USD have been established, with balances of RMB 108.29 million and USD 0 as of July 2, 2025 [4]. - The funds in these accounts are exclusively for the "Thailand Production Base Construction Project" and cannot be used for other purposes [4]. - The sponsor has the right to supervise the use of funds and can conduct on-site investigations and inquiries [5][6]. - Any withdrawal exceeding RMB 20 million within a 12-month period must be reported to the sponsor [6].

宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 证券代码：301097 证券简称：天益医疗 公告编号：2025-038 并签署募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"或"公司"）于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》，同意变更募集资金用途，同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目"，并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目"；同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日，公司已完成部分募集资金专项账户的开立及募集资金三 方监管协议的签署，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开发行股票注册的批复》（证监许可 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2025-037 宁波天益医疗器械股份有限公司 特此公告。 宁波天益医疗器械股份有限公司董事会 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 一次性使用连续 | 国械注准 | | 2025 | 年 5 | 月 | 30 | 日至 | 供连续性肾脏替 代治疗（CRRT） 时作为血液及液 | | 1 | 性肾脏替代治疗 | 2025310111 | III | | | | | | | | | 管路 | 2 | | 2030 | 年 | 月 5 | 29 | 日 | | | | | | | | | | | | 体通道使用。 | | 2 | | | | | | | | | 用于急、慢性肾功 能衰竭患者的血 | | | | | | | | | | | 液透析、血液透析 | | | 一次性使用血液 | 国械注准 | III | 2025 | 年 5 | 月 | 30 | 日至 ...